Anirvan Ghosh - May 11, 2023 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Role
Chief Executive Officer, Director
Signature
/s/ Alexander Nguyen, Attorney-in-Fact for Anirvan Ghosh
Stock symbol
UBX
Transactions as of
May 11, 2023
Transactions value $
$373,950
Form type
4
Date filed
5/12/2023, 08:03 PM
Previous filing
May 3, 2023
Next filing
Jun 15, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UBX Stock Option (Right to Buy) Award $374K +135K $2.77 135K May 11, 2023 Common Stock 135K $2.77 Direct F1
transaction UBX Stock Option (Right to Buy) Disposed to Issuer $0 -25K -100% $0.00* 0 May 11, 2023 Common Stock 25K $29.40 Direct F2, F3
transaction UBX Stock Option (Right to Buy) Award $0 +25K $0.00 25K May 11, 2023 Common Stock 25K $2.77 Direct F2, F3
transaction UBX Stock Option (Right to Buy) Disposed to Issuer $0 -15K -100% $0.00* 0 May 11, 2023 Common Stock 15K $59.75 Direct F4, F5
transaction UBX Stock Option (Right to Buy) Award $0 +15K $0.00 15K May 11, 2023 Common Stock 15K $2.77 Direct F4, F5
transaction UBX Stock Option (Right to Buy) Disposed to Issuer $0 -29K -100% $0.00* 0 May 11, 2023 Common Stock 29K $41.80 Direct F6, F7
transaction UBX Stock Option (Right to Buy) Award $0 +29K $0.00 29K May 11, 2023 Common Stock 29K $2.77 Direct F6, F7
transaction UBX Stock Option (Right to Buy) Disposed to Issuer $0 -56.7K -100% $0.00* 0 May 11, 2023 Common Stock 56.7K $10.60 Direct F8, F9
transaction UBX Stock Option (Right to Buy) Award $0 +56.7K $0.00 56.7K May 11, 2023 Common Stock 56.7K $2.77 Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date.
F2 The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on September 13, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
F3 On May 11, 2023, the option originally granted to the Reporting Person on September 13, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
F4 The underlying shares vest and become exercisable pursuant to the following schedule: Twenty five percent (25%) of the shares subject to the option vested on January 29, 2022 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
F5 On May 11, 2023, the option originally granted to the Reporting Person on January 29, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
F6 Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F7 On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
F8 The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
F9 On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022, was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.